Venus Remedies Ltd

Venus Remedies announced that the 37th Annual General Meeting(AGM) of the company will be held on 20 August 2026.

Venus Remedies announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Net profit of Venus Remedies rose 126.19% to Rs 47.50 crore in the quarter ended March 2026 as against Rs 21.00 crore during the previous quarter ended March 2025. Sales rose 33.05% to Rs 259.40 crore in the quarter ended March 2026 as against Rs 194.97 crore during the previous quarter ended March 2025. For the full year,net profit rose 126.81% to Rs 102.79 crore in the year ended March 2026 as against Rs 45.32 crore during the previous year ended March 2025. Sales rose 17.88% to Rs 769.60 crore in the year ended March 2026 as against Rs 652.89 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales259.40194.97 33 769.60652.89 18 OPM %24.4514.87 -19.1410.50 - PBDT68.3635.75 91 159.8284.42 89 PBT61.6131.04 98 134.1661.91 117 NP47.5021.00 126 102.7945.32 127 Powered by Capital Market - Live

Net profit of Venus Remedies rose 193.78% to Rs 43.45 crore in the quarter ended March 2026 as against Rs 14.79 crore during the previous quarter ended March 2025. Sales rose 31.65% to Rs 259.01 crore in the quarter ended March 2026 as against Rs 196.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 88.98% to Rs 99.31 crore in the year ended March 2026 as against Rs 52.55 crore during the previous year ended March 2025. Sales rose 19.28% to Rs 768.73 crore in the year ended March 2026 as against Rs 644.47 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales259.01196.74 32 768.73644.47 19 OPM %22.9512.83 -18.7211.64 - PBDT64.0829.33 118 155.3790.77 71 PBT57.5724.84 132 130.6869.15 89 NP43.4514.79 194 99.3152.55 89 Powered by Capital Market - Live

Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets. Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.

Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Net profit of Venus Remedies rose 30.51% to Rs 25.58 crore in the quarter ended December 2025 as against Rs 19.60 crore during the previous quarter ended December 2024. Sales rose 2.12% to Rs 180.26 crore in the quarter ended December 2025 as against Rs 176.52 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales180.26176.52 2 OPM %20.8110.21 - PBDT40.0320.38 96 PBT33.4714.97 124 NP25.5819.60 31 Powered by Capital Market - Live

Venus Remedies will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live

Venus Remedies has received marketing authorisation in Indonesia for its antibiotic combination Ceftazidime + Avibactam, granted by the relevant Indonesian drug regulatory authority. This approval marks the first marketing authorisation for Ceftazidime + Avibactam for the Company in Indonesia. The product is indicated for the treatment of serious infections caused by multi-drug resistant gram-negative pathogens, including complicated intra-abdominal infections and complicated urinary tract infectionsPowered by Capital Market - Live

Zuari Industries Ltd, Vipul Ltd, Orient Ceratech Ltd and Urban Company Ltd are among the other gainers in the BSE's 'B' group today, 11 November 2025.Venus Remedies Ltd spiked 14.69% to Rs 538 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 27045 shares were traded on the counter so far as against the average daily volumes of 1651 shares in the past one month. Zuari Industries Ltd soared 12.02% to Rs 343. The stock was the second biggest gainer in 'B' group. On the BSE, 66349 shares were traded on the counter so far as against the average daily volumes of 13731 shares in the past one month. Vipul Ltd surged 9.89% to Rs 9.33. The stock was the third biggest gainer in 'B' group. On the BSE, 30899 shares were traded on the counter so far as against the average daily volumes of 64353 shares in the past one month. Orient Ceratech Ltd added 9.71% to Rs 39.09. The stock was the fourth biggest gainer in 'B' group. On the BSE, 54188 shares were traded on the counter so far as against the average daily volumes of 5194 shares in the past one month. Urban Company Ltd jumped 8.11% to Rs 143.95. The stock was the fifth biggest gainer in 'B' group. On the BSE, 11.44 lakh shares were traded on the counter so far as against the average daily volumes of 6.48 lakh shares in the past one month. Powered by Capital Market - Live